Back to Search Start Over

Etramp5 as a useful serological marker in children to assess the immediate effects of mass drug campaigns for malaria.

Authors :
Druetz T
van den Hoogen L
Stresman G
Joseph V
Hamre KES
Fayette C
Monestime F
Presume J
Romilus I
Mondélus G
Elismé T
Cooper S
Impoinvil D
Ashton RA
Rogier E
Existe A
Boncy J
Chang MA
Lemoine JF
Drakeley C
Eisele TP
Source :
BMC infectious diseases [BMC Infect Dis] 2022 Jul 26; Vol. 22 (1), pp. 643. Date of Electronic Publication: 2022 Jul 26.
Publication Year :
2022

Abstract

Introduction: Serological methods provide useful metrics to estimate age-specific period prevalence in settings of low malaria transmission; however, evidence on the use of seropositivity as an endpoint remains scarce in studies to evaluate combinations of malaria control measures, especially in children. This study aims to evaluate the immediate effects of a targeted mass drug administration campaign (tMDA) in Haiti by using serological markers.<br />Methods: The tMDA was implemented in September-October 2018 using sulfadoxine-pyrimethamine and single low-dose primaquine. A natural quasi-experimental study was designed, using a pretest and posttest in a cohort of 754 randomly selected school children, among which 23% reported having received tMDA. Five antigens were selected as outcomes (MSP1-19, AMA-1, Etramp5 antigen 1, HSP40, and GLURP-R0). Posttest was conducted 2-6 weeks after the intervention.<br />Results: At baseline, there was no statistical difference in seroprevalence between the groups of children that were or were not exposed during the posttest. A lower seroprevalence was observed for markers informative of recent exposure (Etramp5 antigen 1, HSP40, and GLURP-R0). Exposure to tMDA was significantly associated with a 50% reduction in the odds of seropositivity for Etramp5 antigen 1 and a 21% reduction in the odds of seropositivity for MSP119.<br />Conclusion: Serological markers can be used to evaluate the effects of interventions against malaria on the risk of infection in settings of low transmission. Antibody responses against Etramp5 antigen 1 in Haitian children were reduced in the 2-6 weeks following a tMDA campaign, confirming its usefulness as a short-term marker in child populations.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1471-2334
Volume :
22
Issue :
1
Database :
MEDLINE
Journal :
BMC infectious diseases
Publication Type :
Academic Journal
Accession number :
35883064
Full Text :
https://doi.org/10.1186/s12879-022-07616-8